ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,325
-0,69%
Bitcoin
69 171,17
-2,25%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Invivyd Inc (IVVD)

  7. Invivyd Inc (IVVD) Actualités

IVVD

Invivyd (IVVD)

Invivyd Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IVVD
DateHeureSourceTitreSymboleSociété
06/06/202422h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IVVDInvivyd Inc
06/06/202422h57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IVVDInvivyd Inc
03/06/202422h01GlobeNewswire Inc.Invivyd to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:IVVDInvivyd Inc
31/05/202413h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
31/05/202413h05GlobeNewswire Inc.Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for SerialNASDAQ:IVVDInvivyd Inc
31/05/202413h00GlobeNewswire Inc.Invivyd Announces the Appointment of Timothy Lee as Chief Commercial OfficerNASDAQ:IVVDInvivyd Inc
29/05/202413h00GlobeNewswire Inc.Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)NASDAQ:IVVDInvivyd Inc
22/05/202413h00GlobeNewswire Inc.Invivyd Elects Two New Independent Members to its Board of DirectorsNASDAQ:IVVDInvivyd Inc
16/05/202422h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IVVDInvivyd Inc
13/05/202422h01GlobeNewswire Inc.Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:IVVDInvivyd Inc
09/05/202422h32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IVVDInvivyd Inc
09/05/202422h20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IVVDInvivyd Inc
09/05/202422h01GlobeNewswire Inc.Invivyd Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:IVVDInvivyd Inc
07/05/202413h30GlobeNewswire Inc.Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA FeedbackNASDAQ:IVVDInvivyd Inc
02/05/202423h13GlobeNewswire Inc.Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business HighlightsNASDAQ:IVVDInvivyd Inc
30/04/202413h30GlobeNewswire Inc.Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash PositionNASDAQ:IVVDInvivyd Inc
15/04/202413h30GlobeNewswire Inc.Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™NASDAQ:IVVDInvivyd Inc
12/04/202413h30GlobeNewswire Inc.Invivyd Announces CEO TransitionNASDAQ:IVVDInvivyd Inc
04/04/202422h01GlobeNewswire Inc.Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionNASDAQ:IVVDInvivyd Inc
28/03/202412h00GlobeNewswire Inc.Invivyd Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:IVVDInvivyd Inc
22/03/202420h28GlobeNewswire Inc.Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical TrialNASDAQ:IVVDInvivyd Inc
22/03/202420h04GlobeNewswire Inc.Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19NASDAQ:IVVDInvivyd Inc
12/02/202422h01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IVVDInvivyd Inc
09/02/202422h47Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IVVDInvivyd Inc
05/02/202422h02GlobeNewswire Inc.Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:IVVDInvivyd Inc
03/01/202413h00GlobeNewswire Inc.Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and AdolescentsNASDAQ:IVVDInvivyd Inc
22/12/202322h51Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IVVDInvivyd Inc
18/12/202313h00GlobeNewswire Inc.Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19NASDAQ:IVVDInvivyd Inc
09/11/202322h01GlobeNewswire Inc.Invivyd Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:IVVDInvivyd Inc
02/11/202321h01GlobeNewswire Inc.Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:IVVDInvivyd Inc
 Showing the most relevant articles for your search:NASDAQ:IVVD

Dernières Valeurs Consultées

EU
LR
Legrand
EU
DG
Vinci
EU
AF
Air FranceKLM
NASDAQ
MSFT
Microsoft
NASDAQ
AMZN
Amazon.com
NYSE
MRK
Merck
EU
VIV
Vivendi
EU
MC
Lvmh Moet Hennessy Louis...
NYSE
NKE
Nike
EU
HO
Thales
EU
CAP
Capgemini
EU
RNO
Renault
EU
PX1
CAC 40
EU
ACA
Credit Agricole
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés